Researcher

James Allison

Profile

Institution

MD Anderson Cancer Center

Field

Cancer Immunology

James Allison shared the 2018 Nobel Prize in Physiology or Medicine for discovering that blocking the immune checkpoint protein CTLA-4 unleashes T cells to attack tumors, founding the field of immune checkpoint therapy. His work became the drug ipilimumab, the first checkpoint inhibitor approved by the FDA. He chairs the Department of Immunology at MD Anderson and is also an accomplished harmonica player.

Industry Ties

Industry Ties

Bristol-Myers SquibbJounce TherapeuticsTizona Therapeutics

Verified employment, education, publications and profile data sourced from ORCID. Locked — unlock to view.

Fields

• Cancer Immunology